Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
Rhea-AI Summary
Dyadic (Nasdaq: DYAI) will report full year 2025 financial results and host a corporate update conference call on Wednesday, March 25, 2026 at 5:00 p.m. ET.
The live call will use dial-in numbers and a webcast; an archive will be available within 24 hours on the company's Investor Relations website. Investors may submit Q&A questions in advance by email.
Positive
- None.
Negative
- None.
News Market Reaction – DYAI
In the Mar 12 session, DYAI declined 4.57%, reflecting a moderate negative market reaction. Argus tracked a trough of -8.2% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Product launch | Positive | +4.4% | Launch of animal-origin-free recombinant DNase I under Fermbox collaboration. |
| Mar 02 | Commercial milestone | Positive | -1.7% | Planned 2026 commercialization of non-animal dairy enzyme and $200,000 milestone. |
| Feb 17 | Product launch | Positive | -3.0% | Commercial launch of AlbuFree DX recombinant human albumin with profit sharing. |
| Dec 17 | Collaboration expansion | Positive | -1.4% | Expanded Fermbox collaboration to scale and co-commercialize animal-free proteins. |
| Dec 15 | Commercial partnership | Positive | -9.3% | Partnership with Opes Diagnostics to distribute recombinant growth factors and proteins. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent partnership and commercialization announcements were generally positive, but the stock more often traded lower on these updates, showing frequent divergence between news tone and next-day price moves.
Over the last several months, Dyadic announced multiple commercialization and partnership milestones, including new recombinant protein launches and expanded collaborations on Dec 15, 2025, Dec 17, 2025, Feb 17, 2026, Mar 2, 2026, and Mar 4, 2026. Despite the constructive tone of these updates, shares often declined in the following session, with only the most recent product launch on Mar 4, 2026 seeing a positive reaction. Today’s scheduling of full-year 2025 results fits into this backdrop of ongoing commercial progress.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026.
Conference Call Information
Date: Wednesday, March 25, 2026
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: +1-877-407-9219 / +1 412-652-1274
Conference ID: 13758915
Webcast Link:. https://event.choruscall.com/mediaframe/webcast.html?webcastid=KTBXw5BI. An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
If you have any questions that you would like to ask management during the Q&A session, please email jlavalley@dyadic.com prior to the conference call.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information, please visit www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at www.dyadic.com.
Contact:
Ping Rawson
Dyadic Applied BioSolutions
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
